With the number of people in the UK living with reduced vision predicted to almost double to four million by 2050, and nearly nine million currently treated annually by hospital eye services (RCOphth, 2016), there has never been a greater need for updated clinical guidelines and an ironing out of inconsistencies in treatment for cataract, age-related macular degeneration (AMD) and glaucoma. NICE guidelines are based on the best available evidence, with a reputation for rigour, independence and objectivity, and are considered to be the gold standard for clinical practice and cost-effectiveness.

Login to read the rest of this article.